

# **HIV Infection and Pregnancy**

## **Managing Mother and Baby**



**A Train-the-Trainer Program  
for Reducing Perinatal HIV Transmission**

*Sponsored by:*

National Pediatric & Family HIV Resource Center  
François-Xavier Bagnoud Center

This project is funded through a cooperative agreement to NPHRC  
from the U.S. Centers for Disease Control and Prevention (Grant #R62/CCR217856-01-1)

**Table of Contents**

HIV Infection and Pregnancy:  
Managing Mother and Baby

Agenda/Curriculum

---

USPHS  
Perinatal Guidelines

---

Slide Set/Speaker Notes

---

Reprinted References

---

Reference List

---

## HIV Infection and Pregnancy Managing Mother and Baby

Date/Place

### *Sample T-O-T Meeting Agenda*

4:00 – 4:15	Welcome & Introductions Overview of the Project	HIV Educator
4:15 – 5:00	Counseling and Testing	RN/Counselor/ CNM/MD
5:00 – 6:00	Strategies to Reduce Perinatal HIV Transmission	OB/Physician/ NP/CNM
6:00 – 6:45	Medical Management of the Pregnant Woman with HIV	ID/Internal Med/FP Physician
6:45 – 7:00	Break for Working Dinner	
7:00 – 8:00	Panel Discussion of Case Studies	All speakers
8:00 – 8:15	Strategies to Promote Practice Change Questions & Answers	HIV Educator
8:15 – 8:30	Closing and Evaluations	

## **Purpose of the Education Program**

To prepare healthcare professionals who provide women's health and/or HIV care to serve as educators of other providers regarding state-of-the-art knowledge about perinatal HIV transmission, HIV counseling and testing in pregnancy and the complex issues surrounding management of HIV infection in pregnancy.

## **Goals of the Faculty Training Workshop**

- ✓ To increase healthcare providers' knowledge of HIV counseling and testing in pregnancy and the medical management of the pregnant woman with HIV infection
- ✓ To encourage healthcare providers to think critically about the multifaceted issues surrounding the care of a pregnant woman with HIV infection, including antiretroviral therapy and reducing perinatal transmission
- ✓ To facilitate development of a network of professionals who are knowledgeable in issues surrounding HIV counseling, testing, and care during pregnancy who will serve as expert trainers and resource individuals for other women's healthcare providers in a state or region

## Objectives

After attending the educational program, the provider will be able to:

1. Discuss the current scientific understanding of the mechanisms of perinatal HIV transmission and factors that influence it
2. Discuss significant research studies in which interventions have been shown to decrease perinatal HIV transmission, in particular the ACTG 076 study
3. Discuss the current Public Health Service guidelines for antiretroviral therapy in pregnancy for the woman's health and to reduce perinatal HIV transmission
4. Describe national recommendations for routine HIV counseling and testing in pregnancy as well as the barriers/issues surrounding this practice
5. Interpret diagnostic tests for HIV that are recommended during pregnancy and discuss follow-up counseling for a positive or a negative HIV test in pregnancy
6. Recognize psychosocial, economic, legal and ethical issues related to counseling and testing pregnant women about HIV transmission and the recommendations for antiretroviral therapy to reduce perinatal HIV transmission in pregnancy
7. Describe the healthcare provider's role in facilitating HIV testing as well as decision-making by a woman who is considering antiretroviral therapy during pregnancy
8. Recognize a range of possible management strategies using case study examples of the pregnant women with HIV infection
9. Examine assumptions that the healthcare provider has about reproductive choices, HIV testing in pregnancy, and antiretroviral therapy to reduce perinatal transmission of HIV

## Educational Materials Provided

For the faculty trainer:

- ☞ Slide set and detailed speaker notes as a PowerPoint® presentation
- ☞ Bibliography and selected references

For the providers attending the presentation:

- 📖 *Guidelines for Use of HIV Antiretroviral Therapy in Pregnancy—labcoat “pocket card”*
- 📖 *U.S. Public Health Service Task Force. Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States.* Available on-line at: [www.aidsinfo.nih.gov](http://www.aidsinfo.nih.gov)

Consumer educational materials:

- 📖 *What Women Need to Know: The HIV Treatment Guidelines for Pregnant Women*

## Using the Curriculum “HIV Infection and Pregnancy: Managing Mother and Baby” to Educate Healthcare Providers

### Learning Strategies

- Didactic presentations—the slide presentation—can convey a large amount of information to an audience in a limited amount of time
- Interactive approaches to education—question and answer periods, case study discussions, role-play, etc.—are more effective in addressing complex clinical problems and provider and community attitudes
- “Take home” materials—the pocket guide for providers and patient education materials—help providers to follow through on changing their practice behaviors
- An approach that uses both didactic and interactive approaches meets providers' expectations, allows for discussion of issues, recognizes the experience of providers while offering new information and approaches, and ***has the potential to change provider practice and health outcomes***

## Options for Using the “Managing Mother and Baby” Curriculum

- ① One-hour session for OB/Gyn, women’s health, and primary care providers  
(Examples might include grand round presentations, workshops at professional meetings, or inservice presentations)

Timeframe for the faculty presentation:

- Slide presentation using the “Managing Mother and Baby” curriculum (40 min.)
- Questions and answers (5 min.)
- Presentation and discussion of one case study (10 min.)
- Handouts for participants: the Provider Guide, the “Pocket Card,” *What Women Need to Know*, counseling and testing information

- ② 1¼ to 2 hour session for OB/Gyn, women’s health, and primary care providers  
(Examples could include workshops at professional meetings or evening seminars)

Timeframe for the faculty presentation:

- Slide presentation using the “Managing Mother and Baby” curriculum (40–50 min.)
- Questions and answers (10 min.)
- Presentation and discussion of two to four case studies (15–30 min.)
- Handouts for participants: the Provider Guide, the “Pocket Card,” *What Women Need to Know*, counseling and testing information

## Objectives for Participants in the Training

After attending the educational program, the participant will be able to:

1. Describe national recommendations for routine HIV counseling and testing in pregnancy
2. Interpret diagnostic tests for HIV that are recommended during pregnancy and discuss follow-up counseling for a positive or a negative HIV test in pregnancy
3. Discuss the current Public Health Service guidelines for antiretroviral therapy in pregnancy for the woman's health and to reduce perinatal HIV transmission
4. Recognize psychosocial, economic, legal and ethical issues related to counseling and testing pregnant women about HIV transmission and the recommendations for antiretroviral therapy to reduce perinatal HIV transmission in pregnancy
5. Describe the healthcare provider's role in facilitating HIV testing as well as decision-making by a woman who is considering antiretroviral therapy during pregnancy

## Evaluation of the Training

Evaluation is a critical part of this project. How effective is this approach in conveying information about reduction of perinatal HIV transmission and encouraging healthcare providers to integrate HIV counseling and testing into routine prenatal care?

Whenever a trained faculty presents the content of “Managing Mother and Baby” to a group of colleagues, participants should be asked to sign in and complete an anonymous evaluation. If the presentation is formal and is granting CMEs or CEUs, some additional forms may be required. Even if the presentation is more informal or involves only a small number of people, please ask participants to complete the evaluation. NPHRC will be conducting a follow-up evaluation of a sample of participants who receive the training.

## HIV and Pregnancy: Managing Mother and Baby

### References

- ACOG Committee Opinion on Obstetric Practice (2000). *Scheduled cesarean delivery and the prevention of vertical transmission of HIV infection (234)*. Washington, DC: The American College of Obstetricians and Gynecologists.
- American Academy of Pediatrics (2000). Technical report: Perinatal human immunodeficiency virus testing and prevention of transmission. *Pediatrics*, 106(6), p e88.
- American Academy of Pediatrics (1999). Human immunodeficiency virus screening: Joint statement of the American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. *Pediatrics*, 104, 128.
- Antiretroviral Pregnancy Registry. PharmaResearch Corp., Wilmington, NC. January 1989-July 2002.
- Bardeguez, A., Shapiro, D.E., Mofenson, L.M. et al. (2003). Effect of cessation of prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. zidovudine *JAIDS*, 32, 170-181.
- Blanche, S., Tardieu, M., Rustin, P., et al. (1999). Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. *Lancet*, 354, 1084-1089.
- Bulterys, M. Landesman, S., Burns, D.N., et al. (1997). Sexual behavior and injection drug use during pregnancy and vertical transmission of HIV-1. *J Acquir Immune Defic Syndr Human Retrovirol*, 15, 76-82.
- Burns, D.N. & Mofenson, L.M.(1999). Paediatric HIV-1 infection. *Lancet*, 354, Su1-Su6.
- Burr, C.K. (2000). Caring for the newborn exposed to HIV infection. *New*
-

*Jersey AIDSline*, 12 (4), 1, 3.

Burr, C.K. (2000). Challenges in the care of women with HIV infection. *New Jersey AIDSline*, 12(3), 1-3.

Burr, C.K. (2000). Obstetrical interventions to reduce perinatal HIV transmission. *New Jersey AIDSline*, 12(2), 1, 3.

Celum, C.L., Coombs, R.W., Jones, M., et al. (1994). Risk factors for repeatedly reactive HIV-1 EIA and indeterminate western blots. *Arch Intern Med*, 154, 1129-1137.

Centers for Disease Control and Prevention (1994). Recommendations of the Public Health Service Task Force on use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. *MMWR*, 43(RR-11), 1-21.

Centers for Disease Control and Prevention (1995). Revised guidelines for prophylaxis against *Pneumocystis carinii* pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. *MMWR*, 44, 1-11.

Centers for Disease Control and Prevention (1998). Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. *MMWR*, 47 (RR-2), 1-30 (and updates <http://www.aidsinfo.nih.gov>).

Centers for Disease Control and Prevention (1998). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. *MMWR*, 47(RR-5), 39-82 (and updates <http://www.aidsinfo.nih.gov>).

Chuachoowong, R., Shaffer, N., Siriwasin, W., et al. (2000). Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. *J Infect Dis*, 181, 99-106.

- Connor, E.M., Sperling, R.S., Gelber, R., et al. (1994). Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. *N Engl J Med*, *331*, 1173.
- Cooper, E.R., Charurat, M., Mofenson, L., et al. (2002). Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 prevention. *JAIDS*, *29*, 484-494.
- Culnane, M., Fowler, M.G., Lee, S.S., et al. (1999). Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. *JAMA*, *281*, 151-157.
- De Cock, K.M., Fowler, M.G., Mercier, E et al (2000). Prevention of mother-to-child HIV transmission in resource-poor countries: Translating research into policy and practice. *JAMA*, *283* (9), 1175-1182.
- Doran, T.I., Parra, E (2000). False-positive and indeterminate human immunodeficiency virus test results in pregnant women. *Arch Fam Med*, *9*, 924-929.
- Dunn, D.T., Brandt, C.D., Krivine, A., et al. (1995). The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. *AIDS*, *9*, F7-F11.
- Eshleman, S.H., Mracna, M., Guay, L.A. et al (2001) Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). *AIDS*, *15*(15), 1951-1957.
- European Collaborative Study (2003). Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. *JAIDS*, *32*, 380-387.

- European Collaborative Study (1999). Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. *AIDS*, *13*, 1377-1385.
- European Mode of Delivery Collaboration (1999). Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomised clinical trial. *Lancet*, *353*, 1035.
- Fowler, M.G., Simonds, R.J., Roongpisuthipong, A. (2000). Update on perinatal HIV transmission. *Pediatric Clinics of North America* *47* (1), 21-38.
- Garcia, P.M., Kalish, L.A., Pitt, J., et al. (1999). Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. *N Engl J Med*, *341*, 394-402.
- Grubert, T..A. (2002). Rates of post operative complications among Human Immunodeficiency Virus-infected women who have undergone obstetric and gynecologic surgical procedures. *Clinical Infectious Diseases*, *34*, 822-830.
- Guay, L.A., Musoke, P., Fleming, T., et al. (1999). Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. *Lancet*, *354*, 795-802.
- Ickovics, J.R., Wilson, T.E., Royce, R.A. et al (2002). Prenatal and postnatal zidovudine adherence among pregnant women with HIV. *JAIDS*, *30*(3), 311-15.
- International Perinatal HIV Group (1999). Mode of delivery and vertical transmission of HIV-1: A meta-analysis from fifteen prospective cohort studies. *N Engl J Med*, *340*, 977.
- Ioannidis, J.P.A., Abrams, E.J., Ammann, A., et al.(2001). Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. *J Infect Dis*, *183*,539-45.

- Kalish, L.A., Pitt, J., Lew, J.F., et al. (1997). Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture. *J Infect Dis*, 175, 712.
- Kass, N.E., Taylor, H.A. & Anderson, J. (2000). Treatment of human immunodeficiency virus during pregnancy: The shift from an exclusive focus on fetal protection to a more balanced approach. *Am J Obstet Gynecol*, 182, 856-859.
- Lindegren, M.L., Byers, R.H., Thomas, P., et al. (1999). Trends in perinatal transmission of HIV/AIDS in the United States. *JAMA*, 282, 531-538.
- Lorenzi, P., Spicher, V.M., Laubereau, B., et al. (1998). Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study. *AIDS*, 12, F241-247.
- McKinney, M.M., McSpirit, S. & Pomeroy, C. (2000). Prenatal HIV prevention practices in a low seroprevalence state. *AIDS Education and Prevention*, 12, 252-262.
- Minkoff, H. (2003). Human immunodeficiency virus infection in pregnancy. *Obstetrics & Gynecology*, 101 (4), 797-810.
- Minkoff, H., Ahdieh, L., Watts, H. et al. (2001). The relationship of pregnancy to the use of highly active antiretroviral therapy. *Am J. Obstet Gynecol*, 184, 1221-1227.
- Minkoff, H., O'Sullivan, M.J. (1998). The case for rapid HIV testing during labor. *JAMA*, 279(21), 1743-1744.
- Miotti, P.G., Taha, TET, Kumwenda, N.I., et al. (1999). HIV transmission through breastfeeding-a study in Malawi. *JAMA*, 282, 744-749.
- Mofenson, L.M., Lambert, J.S., Stieh, E.R., et al. (1999). Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. *N Engl J Med*, 341, 385-393.
-

- Nolan, M., Fowler, M.G. & Mofenson, L.M. (2002). Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. *JAIDS*, *30*(2), 216-229.
- Paul, S.M., Pollet, C., Burr, C.K., Bardeguet, A. & Khanlou, P. 2001. Prevention of perinatal HIV transmission. *New Jersey Medicine*, March, 23-31.
- Rips, J. (1997). Establishing a successful HIV counseling and testing service. *Obstetrics and Gynecology Clinics of North America*, *24*, 873-897.
- Rodriguez, E.M., Mofenson, L.M., Chang, B.H., et al. (1996). Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. *AIDS*, *10*, 273-282.
- Rodriguez, E.J., Spann, C., Jamieson, D., & Lindsay, M. (2001). Postoperative morbidity associated with cesarean delivery among human immunodeficiency virus—seropositive women. *Am J. Obstet Gynecol*, *184*, 1108-1111.
- Royce, R.A., Walter, E.B., Fernandez, M.I., Wilson, T.E., Ickovics, J.R., Simonds, R.J. for the Perinatal Guidelines Evaluation Project. (2001) Barriers to universal prenatal HIV testing in 4 US locations in 1997. *American Journal of Public Health*, *91*, 727-733.
- Saba, J. on behalf of the PETRA Trial Study Team (1999). Interim analysis of early efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1: the PETRA trial. *Sixth Conference on Retroviruses and Opportunistic Infections*, Abstract S-7. January, Chicago, IL
- Shaffer, N., Chuachoowong, R., Mock, P.A., et al. (1999). Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomized controlled trial. *Lancet*, *355*, 773-780.
- Shapiro, D.E., Sperling, R.S., Coombs, R.W. (1999). Effect of zidovudine on perinatal HIV-1 transmission and maternal viral load. *Lancet*, *354*, 156.
-

- Shiramizu, B., Shikuma, K.M., Kamemoto, L. et al (2003). Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. *JAIDS*, 32, 370–374.
- Simonds, R.J., Steketee, R., Nesheim, S., et al. (1998). Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. *AIDS*, 12, 301-308.
- Smith, M.E., and the U.S. Nucleoside Safety Review Working Group (1999). Ongoing nucleoside safety review of HIV-exposed children in U.S. studies [CD-ROM]. *Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants*, Abstract 096. September 1-6, Montreal, Canada
- Sperling, R.S., Shapiro, D.E., McSherry, G.D., et al. (1998). Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. *AIDS*, 12, 1805-1813.
- Stiehm, E.R., Lambert, J.S., Mofenson, L., et al. (1999). Efficacy of zidovudine and hyperimmune HIV immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease; results of the Pediatric AIDS Clinical Trials Group Protocol 185. *J Infect Dis*, 179, 567-575.
- Stein, E., Handelsman, E. & Matthews, R. (2000). Reducing perinatal transmission of HIV: Early diagnosis and interventions during pregnancy. *J. of Midwifery & Women's Health*, 45, 122-129.
- Stringer, J.S.A., Rouse, D., Goldenberg, R. (1999). Prophylactic cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission: The case for restraint. *JAMA*, 281(20), 1946-1949.
- Tuomala, R.E., Kalish, L.A., Zorrilla, C., et al. (1997). Changes in total, CD4+ and CD8+ lymphocytes during pregnancy and 1 year postpartum in human immunodeficiency virus-infected women. *Obstet Gynecol*, 89, 967-974.

- Tuomala, R.E., Shapiro, D., Mofenson, L.M., et al. (2002). Antiretroviral therapy during pregnancy and the risk of an adverse outcome. *N Engl J Med*, 346(24), 1863–1870.
- Turner, B.J., Hauck, W.W., Fanning, R., et al. (1997). Cigarette smoking and maternal-child HIV transmission. *J Acquir Immune Defic Syndr Human Retrovirol*, 14, 327-337.
- Van Dyke, R.B., Korber, B.T., Popek, E., et al. (1999). The Ariel project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. *J Infect Dis*, 179, 319.
- Vitiello, M.A., Smeltzer, C. (1999). HIV, pregnancy, and zidovudine: What do women know? *Journal of the Association of Nurses in AIDS Care*, 10(4), 41-47.
- Wade, N.A., Birkhead, G.S., French, P.T. (1999). Short courses of zidovudine and perinatal transmission of HIV. *N Engl J Med*, 340, 1042-1043.
- Wade, N.A., Birkhead, G.S., Warren, B.L, et al. (1998). Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. *N Engl J Med*, 339, 1409-1414.
- Watts, D.H., Management of human immunodeficiency virus infection in pregnancy. *N Engl J Med*, 346, 1879-91.
- Wilson, T.E., Ickovics, J.R., Fernandez, M.I. et al. (2001). Self-reported zidovudine adherence among pregnant women with human immunodeficiency virus infection in four US states. *Am J Obstet Gynecol*, 184, 1235-1240.